利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.024 秒)

    Non-human mammal model of autoimmune disease having OX40L gene transferred thereinto
    8.
    发明申请
    Non-human mammal model of autoimmune disease having OX40L gene transferred thereinto 审中-公开
    具有转移OX40L基因的自身免疫性疾病的非人哺乳动物模型

    公开(公告)号：US20050034179A1

    公开(公告)日：2005-02-10

    申请号：US10810527

    申请日：2004-03-26

    申请人： Kazuo Sugamura ,  Kazuko Murata

    发明人： Kazuo Sugamura ,  Kazuko Murata

    IPC分类号： A01K67/027 ,  A61K45/00 ,  A61P3/10 ,  A61P37/06 ,  C07K14/705 ,  C12N15/09 ,  C12N15/85 ,  G01N33/15 ,  G01N33/50 ,  G01N33/564

    CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2227/10 ,  A01K2267/0325 ,  A01K2267/0368 ,  C07K14/70575 ,  C12N2830/008

    摘要： The present invention provides a transgenic non-human mammal model of autoimmune disease introduced with an OX40L gene, and a method for using said mammal for screening a therapeutic drug for the autoimmune disease. Transgenic mice wherein OX40L, one of the TNF family molecules, is constantly expressed in T cells, were constructed. These mice developed an autoimmune disease and they were found to be useful as a model of autoimmune disease. The transgenic non-human mammal that develops an autoimmune disease in the present invention can be constructed by expressing the OX40L gene under the control of T cell-specific lck promoter. The transgenic non-human mammal of the present invention develops an autoimmune disease such as interstitial pneumonia, inflammatory bowel disease, splenomegaly or lymphadenopathy, or hyperimmunoglobulinemia, and said mammal can be effectively used for screening a therapeutic drug for these autoimmune diseases.

    摘要翻译： 本发明提供了引入OX40L基因的自身免疫疾病的转基因非人哺乳动物模型，以及使用所述哺乳动物筛选用于自身免疫疾病的治疗药物的方法。 构建其中OX40L（TNF家族分子之一）在T细胞中不断表达的转基因小鼠。 这些小鼠发展为自身免疫性疾病，并且发现它们可用作自身免疫性疾病的模型。 可以通过在T细胞特异性lck启动子的控制下表达OX40L基因来构建本发明中产生自身免疫疾病的转基因非人哺乳动物。 本发明的转基因非人哺乳动物发生间质性肺炎，炎性肠病，脾肿大或淋巴结肿大或超免疫球蛋白血症等自身免疫性疾病，所述哺乳动物可有效用于筛选这些自身免疫性疾病的治疗药物。

    Medicinal composition containing gp34 binding-inhibitor as the active ingredient
    9.
    发明授权
    Medicinal composition containing gp34 binding-inhibitor as the active ingredient 失效
    含有gp34结合抑制剂作为活性成分的药物组合物

    公开(公告)号：US06333035B1

    公开(公告)日：2001-12-25

    申请号：US09308332

    申请日：1999-05-19

    申请人： Kazuo Sugamura ,  Kazuko Murata ,  Norikazu Higashimura

    发明人： Kazuo Sugamura ,  Kazuko Murata ,  Norikazu Higashimura

    IPC分类号： A61K39395

    CPC分类号： C07K16/2875 ,  A61K2039/505

    摘要： The present invention relates to a pharmaceutical composition for the therapeutic treatment of autoimmune diseases including rheumatoid arthritis, multiple sclerosis, sarcoidosis, autoimmune uveitis, and inflammatory bowel disease, or graft-versus-host disease. The pharmaceutical composition contains, as the effective ingredient, a gp34 binding-inhibitory substance.

    摘要翻译： 本发明涉及用于治疗性治疗包括类风湿性关节炎，多发性硬化，结节病，自身免疫性葡萄膜炎和炎症性肠病或移植物抗宿主病的自身免疫性疾病的药物组合物。 药物组合物含有作为有效成分的gp34结合抑制物质。

    .gamma.-chain humaninterleukin-2 receptor polypeptide and method of making
    10.
    发明授权
    .gamma.-chain humaninterleukin-2 receptor polypeptide and method of making 失效
    γ链人类白细胞介素-2受体多肽及其制备方法

    公开(公告)号：US5856140A

    公开(公告)日：1999-01-05

    申请号：US636936

    申请日：1996-04-24

    申请人： Toshiro Shimamura ,  Junji Hamuro ,  Harumi Nakazawa ,  Yuka Kanayama ,  Kazuo Sugamura ,  Toshikazu Takeshita

    发明人： Toshiro Shimamura ,  Junji Hamuro ,  Harumi Nakazawa ,  Yuka Kanayama ,  Kazuo Sugamura ,  Toshikazu Takeshita

    IPC分类号： A61K38/00 ,  C07K14/715 ,  C07K16/28 ,  C12N1/21 ,  C12N15/13 ,  C12P21/08 ,  C12P21/04 ,  C12N1/20 ,  C12N15/00 ,  C12P21/06

    CPC分类号： C07K14/7155 ,  C07K16/2866 ,  A61K38/00

    摘要： A polypeptide which specifically binds to the .gamma.-chain of the human interleukin-2 receptor and selectively inhibits the binding of the .gamma.-chain of human interleukin-2 receptor to the .beta.-chain of the same is provided. The polypeptide has an activity of blocking the human interleukin-2 response. Also provided are an immunosuppressant containing the polypeptide, a DNA gene coding for the polypeptide, a recombinant DNA having the gene, a transformant having the recombinant DNA, and a method for producing the intended polypeptide by incubating the transformant. The novel polypeptide can be used independently, or with substances capable of inhibiting the binding of interleukin-2 to the interleukin-2 receptor, as a medicine for preventing the rejection of grafts after transplantation and also for curing inflammatory diseases such as allergic diseases and autoimmune diseases.

    摘要翻译： 提供了特异性结合人白细胞介素-2受体的γ-链的多肽，并选择性地抑制人白细胞介素-2受体的γ-链与β-链的结合。 该多肽具有阻断人白介素-2应答的活性。 还提供了含有多肽的免疫抑制剂，编码该多肽的DNA基因，具有该基因的重组DNA，具有该重组DNA的转化体，以及通过温育该转化体来制备该多肽的方法。 该新型多肽可以独立使用，也可以与能够抑制白介素-2与白细胞介素-2受体结合的物质用作防止移植后移植物排斥的药物，还可用于治疗炎性疾病如过敏性疾病和自身免疫性 疾病